Camp4 Therapeutics Corp Expected To Post A Loss Of 21 Cents A Share: Earnings Preview

CAMP4 Therapeutics

10/08/2026 12:51

CAMP4 Therapeutics Corp CAMP.OQ CAMP.O is expected to  show a rise in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026
The Cambridge Massachusetts-based  company is expected to report a 26.7% increase in revenue to $1.897 million from $1.5 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for CAMP4 Therapeutics Corp is for a loss of 21 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for CAMP4 Therapeutics Corp is $8.00, about 88.7% above its last closing price of $4.24
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.21
-0.21
-0.32
Missed
-52.4
Dec. 31 2026
-0.31
-0.30
-0.86
Missed
-183.5
Sep. 30 2025
-0.43
-0.48
-0.55
Missed
-15​
Jun. 30 2025
-0.67
-0.67
-0.62
Beat
7.7
​​Mar. 31 2025
-0.70
-0.70
-0.62
Beat
11.4
Dec. 31 2024
-1.22
-0.82
-2.83
Missed
-244.1​
Sep. 30 2024
-1.07
-1.07
-24.19
Missed
-2,155.5
This summary was machine generated August 10 at 11:51 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)